Skip to main content
Fig. 8 | BMC Bioinformatics

Fig. 8

From: High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases

Fig. 8

Therapeutic sensitivity prediction with SLC31A1 in breast cancer. Comparison of the half maximal inhibitory concentration of anti-tumor drugs between high and low SLC31A1 expression groups: A doxorubicin, B docetaxel and C paclitaxel. Immune therapy scores (vertical axis) of anti-CTLA4 and anti-PD1 inhibitors indicating response of D no immunotherapy, E anti-PD1, F anti-CTLA4, G anti-PD1 and anti-CTLA4 therapies between high and low SLC31A1 expression groups

Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us